In Conversation: Reza Khorasani
CEO & Co-Founder, Leadoptik - on how miniaturized metasurface optics deliver real-time imaging from inside a biopsy needle to cut lung cancer biopsy error rates
In a sector where hype routinely outruns delivery, it is worth listening closely to Reza Khorasani, CEO & Co-Founder, Leadoptik. In a wide-ranging conversation conducted by MobiHealthNews, Reza laid out a view of the industry that is both candid and immediately useful to the executives, clinicians, and builders who read HealthTech Cube.
The conversation
How miniaturized metasurface optics deliver real-time imaging from inside a biopsy needle to cut lung cancer biopsy error rates - plus funding and the path to commercialization.
“Lung cancer kills more than the next three cancers combined.”
- Reza Khorasani, in conversation with MobiHealthNews
Conversation highlights
How miniaturized metasurface optics deliver real-time imaging from inside a biopsy needle to cut lung cancer biopsy error rates
Plus funding and the path to commercialization
The bigger picture
The AI adoption question runs through every executive conversation in 2026. The evidence base is finally arriving: the largest controlled study of ambient documentation, published in JAMA, found clinicians saved 16 minutes of documentation time per day - but only a third of users hit the usage threshold for maximum benefit (our coverage). Meanwhile Rock Health has stopped labeling AI as a differentiator at all, because every company claims it - which is exactly why operating discipline of the kind described here separates winners from demo-ware.
The capital context matters here. US digital health raised $7.4 billion in H1 2026 with 45% of it concentrated in $100M+ megadeals, and 115 acquisitions made it the busiest M&A run since 2021 (our analysis). In a market this concentrated, the strategies described in this conversation - defensible data, measurable outcomes, disciplined growth - are precisely what separates the funded from the folded.
What makes the discussion valuable is its refusal to stay abstract: every point lands on a real workflow, budget, or patient. At Leadoptik, that thinking translates into daily decisions about where technology genuinely earns its place in care delivery, and where discipline matters more than novelty.
The HTC take
The through-line matches what our reporting keeps finding across the industry: adoption succeeds where governance, workflow, and evidence move together.